Cargando…
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival
Targeting of the programmed cell death protein (PD)-1/programmed death-ligand 1 (PD-L1) axis has shown a significant clinical impact in several tumor types. Accordingly, our phase II NIBIT-MESO-1 study demonstrated an improved clinical efficacy in mesothelioma patients treated with the anti-PD-L1 du...
Autores principales: | Chiarucci, Carla, Cannito, Sara, Daffinà, Maria Grazia, Amato, Giovanni, Giacobini, Gianluca, Cutaia, Ornella, Lofiego, Maria Fortunata, Fazio, Carolina, Giannarelli, Diana, Danielli, Riccardo, Di Giacomo, Anna Maria, Coral, Sandra, Calabrò, Luana, Maio, Michele, Covre, Alessia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072596/ https://www.ncbi.nlm.nih.gov/pubmed/32033266 http://dx.doi.org/10.3390/cancers12020361 |
Ejemplares similares
-
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study
por: Calabrò, Luana, et al.
Publicado: (2021) -
Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy
por: Lofiego, Maria Fortunata, et al.
Publicado: (2021) -
Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy
por: Fazio, Carolina, et al.
Publicado: (2018) -
Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study
por: Maccalli, Cristina, et al.
Publicado: (2013) -
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation
por: Maio, Michele, et al.
Publicado: (2021)